Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis

Journal of Nephrology

Volumn 17, Issue 1, 2004, Pages 87-94

  Kotzman, Harald ^a   Riedl, Michaela ^a   Pietschmann, Peter ^a   Schmidt, Alice ^a   Schuster, Ernst ^a   Kreuzer, Sören ^a   Kainberger, Franz ^a   Frisch, Herwig ^a   Geyer, Georg ^a   Hörl, Walter H ^a   Mayer, Gert ^a   Luger, Anton ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bone matabolism; Bone mineral density; Chronic hemodialysis; Growth hormone

Indexed keywords

ALKALINE PHOSPHATASE; HUMAN GROWTH HORMONE; OSTEOCALCIN; PARATHYROID HORMONE; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; TELOPEPTIDE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITOMETRY; DOUBLE BLIND PROCEDURE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LUMBAR SPINE; MALE; MALNUTRITION; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL; RENAL OSTEODYSTROPHY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

BONE AND BONES; BONE DENSITY; DENSITOMETRY, X-RAY; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KIDNEY FAILURE, CHRONIC; LUMBAR VERTEBRAE; MALE; MALNUTRITION; MIDDLE AGED; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PROCOLLAGEN; RENAL DIALYSIS; RENAL OSTEODYSTROPHY;

EID: 11144354806     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Malluche HH, Ritz E, Lange HP, Kutschera J, Hodgson M, Seifert U, Schoeppe U. Bone histology in incipient and advanced renal failure. Kidney Int 1976; 9: 355-62.
2. Llach F, Bover J. In Brenner BM, Ed. Renal osteodystrophy in Kidney. Philadelphia: WB Saunders 1996; 2187-273.
3. Stein MS, Packham DK, Ebeling PR, Wark JD, Becker GJ. Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 1996; 28: 515-22.
4. Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrad D . Risk factors for renal osteodystrophy a multivariant analysis. J Bone Miner Res 1995; 10: 149-56.
5. Llach F. Secondary hyperparathyroidism in renal failure: The trade-off hypothesis revisited. Am J Kidney Dis 1995; 25: 663-79.
6. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int 1992; 38 (suppl): S62-7.
7. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, Segre GV, Fenton S, Sherrad DJ. Aplastic osteodystrophy without aluminPumU The role of "suppressed" parathyroid function. Kidney Int 1993; 44: 860-6.
8. Blum WF, Ranke MB, Kietzmann K, Tonshoff B, Mehls O. Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uremia. Pediatr Nephrol 1991; 5: 539-44.
9. Mak RH, Pak Y. End organ resistance to growth hormone and IGF-I in epiphyseal chondrocyte of rats with chronic renal failure. Kidney Int 1996; 50: 400-6.
10. Fouque D, Peng SC, Kopple JP. Impaired metabolic response to recombinant insulin like growth factor-I in dialysis patients. Kidney Int 1995; 47: 876-83.
11. Hill PA, Reynolds JJ, Meikle MC. Osteoblasts mediate insulin-like growth factor I and II stimulation of osteoclast formation and function. Endocrinology 1995; 136: 124-131.
12. Isgaard J, Nilsson A, Lindahl A, Jansson JO, Isakson OG. Effects of local administration of GH and IGF-I on longitudinal bone growth in rats. Am J Physiol 1986; 250: E367-372.
13. Schlechter NL, Russel SM, Spencer EM, Nicoll CS. Evidence suggesting that the direct growth-promoting effect of growth hormone on cartilage in vivo is mediated by local production of somatomedin. Proc Natl Acad Sci U S A 1986; 83: 7931-4.
14. Schoenle E, Zapf J, Humble RE, Froesch E. Insulin-like growth factor I and II stimulates growth in hypophysectomized rats. Nature 1982; 296: 252-3.
15. Wüster CH, Abs R, Bengtsson BA. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001; 16: 398-405.
16. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994; 78: 669-74.
17. Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson BA. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993; 129: 201-6.
18. Kotzmann H, Riedl M, Bernecker P, Clodi M, Kainberger F, Kaider A, Woloszcuk W, Luger A. Effect of long-term growth hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency. Calcif Tissue Int 1998; 62: 40-6.
19. Välimäki MJ, Salmela PI, Salmi J, Viikari J, Kataja M, Turunen H, Soppi E. Effects of 42 months treatment on bone mineral density and bone turnover in GH-deficient adults. Eur J Endocrinol 1990; 140: 545-54.
20. Gram J, Hansen TB, Jensen PB, Christensen JH, Ladefog S, Pedersen FB. The effect of recombinant human growth hormone treatment on bone and mineral metabolism in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1529-34.
21. Kotzmann H, Yilmaz N, Lercher P, Riedl M, Schmidt A, Schuster E, Kreuzer S, Geyer G, Frisch H, Hörl WH, Luger A. Differential effects of growth hormone therapy in malnourished hemodialysis patients. Kidney Int 2001; 60: 1578-85.
22. Salomon F, Cuneo RC, Hesp R, Sönksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-803.
23. Jörgensen JO, Thuesen L, Ingemann-Hansen T, Skakkebaek NE, Christiansen JS. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; 1: 1221-5.
24. Degerblad M, Elgindy N, Hall K, Sjöberg HE. Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocrinol (Copenh) 1992; 126: 387-93
25. Ziegler TR, Lazarus JM, Young LS, Hakim R, Wilmore DW. Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol 1991; 52: 726-30.
26. Iglesias P, Diez JJ, Fernandez-Reyes MJ, Aguilera A, Burgues S, Martinez-Ara J, Miguel J, Gomez-Pan A, Selgar T. Recombinant human growth hormone therapy in malnourished dialysis patients: A randomized controlled study. Am J Kidney Dis 1998; 32: 454-63.
27. Johannsson G, Bengtsson BA, Ahlmen J. Double blind, placebo controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: Anabolic effect and functional improvement. Am J Kidney Dis 1999; 33: 709-17.
28. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical parameters of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999; 56: 1084-93.
29. Piraino B, Chen T, Cooperstein L, Segre G, Puschett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 1988; 30: 57-62.
30. De Vita MV, Rasenas LL, Bansal M, Gleim GW, Zabetakis PM, Gardenschwartz MH, Michelis MF. Assessment of renal osteodystrophy in hemodialysis patients. Medicine 1992; 71: 284-90.
31. Hutschinson AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, Gokal R. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993; 44: 1071-7.
32. Spencer EM, Liu CC, Si EC, Howard GA. In vivo actions of insulin-like growth factor I (IGF-I) on bone formation and resorption in rats. Bone 1991; 12: 21-6.
33. Jonsson KB, Ljunghall S, Karlstrom O, Johansson AG, Mallmin H, Ljunggren O. Insulin-like growth factor 1 enhances the formation of type I collagen in hydrocortisone treated human osteoblasts. Biosci Rep 1993; 13: 297.
34. Marcus R, Butterfield G, Holloway L, Gilliland L, Baylink DJ, Hintz RL, Sherman BM. Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab 1990; 70: 519-27.
35. Johansson AG, Burman P, Westermark K, Ljunghall S. The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor 1. J Intern Med 1992; 232: 447-52.
36. Ljunghall S, Johansson AG, Burman P, Kampe O, Lindh E, Karlsson FA. Low plasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis. J Intern Med 1992; 232: 59-64.
37. Aloia JF, Vaswani A, Kapoor A, Yeh JK, Cohn SH. Treatment of osteoporosis with calcitonin, with or without growth hormone. Metabolism 1995; 34: 124-5.
38. Brunegger M, Hulter HN, Krapf R. Effect of chronic metabolic acidosis on the growth hormone/IGF-I endocrine axis: New cause of growth hormone insensitivity in humans. Kidney Int 1997; 52: 216-21.
39. Malluche HH, Monier-Faugere MC. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994; 4: 1631-42.
40. Eastell R, Bluhmsohn H. The value of biochemical markers of bone turnover in osteoporosis. J Rheumatol 1997; 24: 1215-7.
41. Charhon SA, Delmas PD, Malval L, Chavassieux PM, Arlot M, Chapuy MC, Meunier PJ. Serum bone gla protein in renal osteodystrophy: Comparison with bone histomorphometry. J Clin Endocrinol Metab 1986; 63: 892-7.
42. Hamdy NA, Risteli J, Risteli L, Harris S, Beneton NC, Brown MN, Kanis JA. Serum type I procollagen peptide: A non invasive index of bone formation in patients on hemodialysis. Nephrol Dial Transplant 1994; 9: 511-6.
43. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyrolidine cross-linked carboxyterminal telopeptide of type I collagen: A new marker of collagen degradation. Clin Chem 1993; 39: 35-40.
44. Delmas PD, Wilson DM, Mann KG. Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab 1983; 57: 1028-30.